Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Development of a microfluidic paper analytical device for the measurement of iodide in briny wastewater.

Analytical methods : advancing methods and applications·2026
Same author

Response to letter to the editor: "GLP-1RAs for pouchitis in obesity: what the current study does not tell us".

Inflammatory bowel diseases·2026
Same author

Atomically dispersed cobalt on niobium oxide enables photothermal nitrogen fixation via nitrogen-hydrogen coupling.

Journal of colloid and interface science·2026
Same author

Glucagon-Like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease: A Narrative Review.

Gastro hep advances·2026
Same author

Baseline Lymphopenia Predicts Survival in ICI-Naïve Solid Tumor Patients Receiving Immune Checkpoint Inhibitors: A Propensity-Matched Real-World Pan-Cancer Analysis.

Cancers·2026
Same author

Strengthening STD Screening Programs: Comprehensive Evaluation of High-Throughput Immunoassays for HIV and Syphilis Detection.

Microorganisms·2026

相关实验视频

Updated: Sep 10, 2025

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

12.7K

固体瘤中的HER2变异:对综合测试的含义

Ahmed Ismail1,2, Chimay Jani3, Nusrat Jahan1

  • 1Section of Hematology & Oncology, Department of Medicine, The University of Alabama at Birmingham and O'Neal Comprehensive Cancer Center, Birmingham, AL, USA.

The oncologist
|August 19, 2025
PubMed
概括
此摘要是机器生成的。

了解不同癌症中的ERBB2 (HER2) 变化对于向治疗至关重要. 全面的基因组和蛋白质分析对于准确的患者鉴定和治疗至关重要.

关键词:
副本数量变化的变化在ERBB2中,它是ERBB2.在HER2中,HER2是HER2.在HER2突变状态下.在HER2过度表达的过程中,HER2过度表达.免疫组织化学 免疫组织化学

更多相关视频

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

273
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.1K

相关实验视频

Last Updated: Sep 10, 2025

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

12.7K
Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

273
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.1K

科学领域:

  • 在瘤学瘤学.
  • 基因组学就是基因组学.
  • 分子诊断学 分子诊断

背景情况:

  • ERBB2 (HER2) 变化是瘤进展的关键驱动因素,特别是在非乳腺和胃癌中.
  • 针对HER2的治疗方法,如Trastuzumab deruxetecan (T-DXd),已经获得了全瘤批准.
  • 在各种癌症类型中表征ERBB2变化对于扩大患者接受这些疗法的资格至关重要.

研究的目的:

  • 为了研究ERBB2变化的频谱和临床意义,在各种各样的固体瘤队列.
  • 评估ERBB2基因拷贝数变异 (CNV) 和HER2蛋白表达 (IHC) 之间的相关性.
  • 评估ERBB2突变的患病率及其与HER2蛋白水平和CN放大关系.

主要方法:

  • 分析了653个实体瘤样本,使用免疫组织化学 (IHC),复制数变异 (CNV) 评估和突变分析.
  • 评估CN放大和IHC表达之间的关联,使用索默斯的D顺序关联.
  • 致病性ERBB2突变与IHC分数和CN放大状态的相关性.

主要成果:

  • 在3.1%的病例中,HER2 IHC评分显示为3+,在13.2%的病例中显示为2+,在19.8%的病例中显示为1+;63.9%的病例是IHC阴性.
  • 在3.1%的瘤中发生了ERBB2 CN放大,其中75%显示IHC3+. 在3.1%的患者中发现了致病突变,IHC3+率较低 (5%).
  • 在ERBB2 CNV和IHC表达之间观察到强烈的正相关性 (Somers' D = 0.73,p < 0.001).

结论:

  • 在各种癌症中,ERBB2的改变是异质的,这强调了它们的临床意义.
  • 具有ERBB2突变的瘤通常表现出较低的HER2蛋白表达或CN放大,需要全面的基因组测试.
  • 整合基因组和表型数据对于精确的诊断和针对HER2向治疗的最佳治疗决策至关重要.